Advertisement

Topics

Biogen Idec Inc. Company Profile

08:12 EDT 27th May 2018 | BioPortfolio

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.


News Articles [322 Associated News Articles listed on BioPortfolio]

wikifolio whispers p.m. zu Baumot Group, Innogy, Biogen Idec ...

Aktuelle Kommentare aus dem wikifolio-Universum. Mit Links zu den jeweiligen Depots, damit man sieht, wie erfolgreich die Kommentatoren mit ihren Einschätzungen sind und wie sich die genannten Inpu.....

Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe

Biogen expects to launch IMRALDI in Europe on October 16, 2018 Biogen will be the first company to offer biosimilars of all three major anti-TNF therapies in Europe Biogen Inc. (Nasdaq: BIIB) and ...

Biogen, Neurimmune Announce Option Exercise For Aducanumab

NewsBiogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 i...

Biogen, Ionis Expand Collaboration; Biogen To Pay $1 Bln To License Therapies

WESTON (dpa-AFX) - Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced they have expanded strategic collaboration through a new ten-year collaboration agreement to develop antisense drug cand...

Biogen-Aktie: Fehlschlag sollte nicht von Erfolgschancen ablenken! - Aktienanalyse

New York - Biogen-Aktienanalyse von Analyst Michael Yee von Jefferies & Co: Aktienanalyst Michael Yee vom Investmenthaus Jefferies & Co empfiehlt die Aktien des US-Biotechkonzerns Biogen Inc. (ISIN...

Biogen to Acquire Phase 2-Ready Schizophenia Drug from Pfizer

Biogen is entering neuropsychiatry drug development with a deal to acquire a schizophrenia drug candidate from Pfizer. Cambridge, MA-based Biogen (NASDAQ: BIIB) is paying Pfizer $75 million up front f...

Biogen boosts pipeline with $1bn Ionis deal

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its $1 billion drug development deal with Ionis Pharmaceuticals. Perhaps signifying the ...

Biogen to buy Pfizer's neurology drug in deal nearing US$600 million

Biogen Inc said on Monday it would buy Pfizer Inc's experimental treatment for cognitive impairment associated with schizophrenia in a deal whose value could near US$600 million. FILE PHOTO: A sig...

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Indium in 111 chloride [Mallinckrodt Inc.]

Indiclorhigh purity indium chloride in-111 sterile solution [Amersham Health]

INDICLORHigh Purity Indium Chloride In-111 Sterile Solution

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.

Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion mole...

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled I...

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never b...

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is ...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Companies [34 Associated Companies listed on BioPortfolio]

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec and Portola Pharmaceuticals

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more t...

More Information about "Biogen Idec Inc." on BioPortfolio

We have published hundreds of Biogen Idec Inc. news stories on BioPortfolio along with dozens of Biogen Idec Inc. Clinical Trials and PubMed Articles about Biogen Idec Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Idec Inc. Companies in our database. You can also find out about relevant Biogen Idec Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record